National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 26 of 41
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
NCT00056797
Screening Protocol for HIV Vaccine Studies
NCT00031304
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
NCT00031343
Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency
NCT00031005
Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants
NCT00386035
Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants
NCT00385632
Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)
NCT00028236
Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers
NCT00027482
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
NCT00029107
Treatment of Multiple Sclerosis With Copaxone and Albuterol
NCT00039988
G-CSF to Treat Crohn's Disease
NCT00025805
Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load
NCT00025922
Intermittent vs. Continuous HAART to Treat Chronic HIV Infection
NCT00025909
Impact of Gender on Patients
NCT00170560
Funguria in Hospitalized Patients
NCT00138502
Neonatal CMV-Ganciclovir Follow-up Study
NCT00031421
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
NCT00034528
Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care
NCT00023192
Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
NCT00023153
Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
NCT00016718
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
NCT00021567
Pleconaril Enteroviral Sepsis Syndrome
NCT00031512
Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women
NCT00016601
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
NCT00017862
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
NCT00018031
Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs
NCT00017771
Identification of Viruses Associated With Diseases of Unknown Cause
NCT00359268
Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2
NCT00050726
Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms
NCT00015431
Islet Transplantation for Type 1 Diabetes
NCT00014911
Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People
NCT00053430
Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
NCT00015665
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
NCT00013689
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
NCT00005762
Racial Difference in HCV/Host Interactions
NCT00071916
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
NCT00013702
HIV Maintenance Therapy With T-20 During HAART Interruption
NCT00013884
Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
NCT00011011
Pediatric Kidney Transplant Without Calcineurin Inhibitors
NCT00023231
Anti-CD20 in Systemic Lupus Erythematosus
NCT00036491
Effects of Storage on Lactate in Blood Samples
NCT00011050
HIV-1 Vaccine Test in Uninfected Adult Volunteers
NCT00009685
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
NCT00023244
Monoclonal Antibody Treatment of Crohn's Disease
NCT00007163
Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
NCT00134875
Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs
NCT00006494
The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women
NCT00006444
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
NCT00058734
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
NCT00006604
HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs
NCT00007488
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.